(February 28 21:08) Forbes.com
Generative AI technology, like ChatGPT, is disrupting many industries
including biopharma. For example, Absci is using AI to design & validate de novo antibodies. And now Absci is expanding its
operation to Europe to disrupt the protein-based therapeutics market.
You can find the original article
here